Coherus BioSciences Inc Total Liabilities
Coherus BioSciences Inc total liabilities. Based on the latest financial reports, Coherus BioSciences Inc (CHRS) has total liabilities worth $130.34 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check CHRS cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Coherus BioSciences Inc (2012–2025)
Total liabilities of Coherus BioSciences Inc from 2012 to 2025. This chart illustrates how Coherus BioSciences Inc's total liabilities have evolved over time, based on quarterly financial data.
Coherus BioSciences Inc Competitors by Total Liabilities
The table below lists competitors of Coherus BioSciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Compañía Minera Autlán S.A.B. de C.V
MX:AUTLANB
|
Mexico | MX$407.26 Million |
|
Synalloy Corporation
NASDAQ:ACNT
|
USA | $20.97 Million |
|
BAOZUN INC. A DL -0001
F:2BZ
|
Germany | €4.20 Billion |
|
Founding Construction Development Co Ltd
TW:5533
|
Taiwan | NT$2.17 Billion |
|
Duluth Holdings Inc
NASDAQ:DLTH
|
USA | $236.49 Million |
|
Argent
JSE:ART
|
South Africa | ZAC836.08 Million |
|
Moens Bank A/S
CO:MNBA
|
Denmark | Dkr4.78 Billion |
|
Hwa Fong Rubber Ind Co Ltd
TW:2109
|
Taiwan | NT$2.87 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Coherus BioSciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Coherus BioSciences Inc (CHRS) total assets.
Liquidity & Leverage Metrics
Coherus BioSciences Inc Total Liabilities Ratios Explained
Coherus BioSciences Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.68 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Coherus BioSciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Coherus BioSciences Inc (2012–2025)
The table below shows the annual total liabilities of Coherus BioSciences Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $197.33 Million | -66.01% |
| 2024-12-31 | $580.52 Million | -29.47% |
| 2023-12-31 | $823.03 Million | +33.12% |
| 2022-12-31 | $618.26 Million | +6.30% |
| 2021-12-31 | $581.61 Million | +3.73% |
| 2020-12-31 | $560.67 Million | +84.61% |
| 2019-12-31 | $303.71 Million | +119.99% |
| 2018-12-31 | $138.06 Million | +4.53% |
| 2017-12-31 | $132.08 Million | -17.00% |
| 2016-12-31 | $159.13 Million | -27.44% |
| 2015-12-31 | $219.31 Million | +82.06% |
| 2014-12-31 | $120.46 Million | +34.10% |
| 2013-12-31 | $89.83 Million | +418.02% |
| 2012-12-31 | $17.34 Million | -- |
About Coherus BioSciences Inc
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin… Read more